Clozapine-Related Adverse Events and Managing Inadequate Response-View Presentation

Video Transcription

Video Summary

Dr. Jonathan Meyer reviews practical management of clozapine adverse effects and inadequate response. He emphasizes early use of metformin to prevent or reduce clozapine-related weight gain and metabolic problems, recommending slow titration and extended-release formulations when needed. He argues that seizures are uncommon, usually manageable, and should not prompt clozapine discontinuation; prophylactic anticonvulsants are generally unnecessary for more than 98% of patients. If a seizure occurs, clinicians should look for reversible causes such as dose increases, drug interactions, smoking cessation, or abrupt alcohol/benzodiazepine changes. Valproate is the preferred anticonvulsant when needed, but it carries important risks, including weight gain and neutropenia.<br /><br />He also reviews how to evaluate fever during the first 6–8 weeks of treatment, when myocarditis and interstitial nephritis are most likely. Key tests include troponin and CRP for myocarditis, and creatinine/GFR plus urinalysis for nephritis. Benign fever and eosinophilia are common and do not automatically require stopping clozapine. Long-term cardiomyopathy, enuresis, and several hematologic abnormalities are also discussed. Finally, he stresses that poor clozapine response often reflects underdosing or nonadherence, and that dose optimization, augmentation, or ECT may help when clozapine alone is insufficient.

Keywords

clozapine adverse effects

metformin

weight gain

seizure management

myocarditis

interstitial nephritis

valproate

dose optimization

electroconvulsive therapy